Table 5 Clinical results at the end of radiotherapy.
From: Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy
Duration of RT [days] | Mean ± SD [range] | 58 ± 4 [52-66] |
|---|---|---|
PSA pre-RT [μg/l] | Median ± MAD [range] | 6.7 ± 3.6 [0.1, 26.0] |
PSA post-RT [μg/l] | Median ± MAD [range] | 0.4 ± 0.4 [0.0, 6.8] |
Rectal acute toxicity | G0 | 31/43 (72%) |
G1 | 12/43 (28%) | |
G2 | 0/43(0%) | |
G3 | 0/43(0%) | |
Urinary acute toxicity (disuria) | G0 | 8/42 (19%) |
G1 | 29/42 (69%) | |
G2 | 5/42 (12%) | |
G3 | 0/42 (0%) | |
Erectile function | Yes | 14/41 (34%) |
Yes/No | 4/41 (10%) | |
No | 23/41 (56%) |